Philips' Verida Spectral CT Receives FDA Clearance

Philips has announced that its Verida spectral CT system has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA), introducing its advanced AI-powered spectral CT technology to the U.S. market. This innovation represents a significant advancement in diagnostic imaging, integrating continual spectral imaging with AI reconstruction to enhance clinical precision in various fields, including radiology, cardiology, and oncology.

The Philips Spectral CT Verida system features the Spectral Precise Image, utilizing a third-generation Nano-panel Precise dual-layer detector and an AI-based deep learning reconstruction engine. This system is designed to optimize image de-noising and improve image quality across CT applications. It allows clinicians to tailor the image noise reduction to their specific needs. By combining always-active spectral imaging with AI-enhanced reconstruction, Verida enhances first-time-right imaging, potentially leading to quicker and better-informed clinical decisions.

Dan Xu, the Business Leader of CT at Philips, stated, "With FDA clearance for Verida, we are bringing the next evolution of spectral CT to more markets." He emphasized the benefits of combining spectral imaging with AI capabilities, enabling clinicians to achieve more accurate and comprehensive diagnostics on the first attempt and broadening CT's role in clinical workflows.

The Verida system leverages Philips’ detector-based spectral CT technology, facilitating spectral imaging without needing additional scans or workflow adjustments. System and software updates have been integrated to streamline the clinical workflow, improving the spectral result generation pipeline and computing infrastructure. Verida can reconstruct up to 145 images per second, enabling complete examinations to appear in under 30 seconds, significantly enhancing throughput to up to 270 exams per day.

The system functions by capturing both high- and low-energy data in a single acquisition, providing clinicians simultaneous access to conventional and spectral results. This functionality aids in more precise tissue characterization and material differentiation. Verida is suitable for diagnostic imaging across a range of applications, including radiology, interventional radiology, and cardiology. It is used in treatment planning for oncology and supports low-dose CT lung cancer screening within established protocols.

Philips’ Verida spectral CT system is poised to positively impact diagnostic imaging, supporting enhanced insight across diverse clinical applications.